Compare BridgeBio Pharma Inc (BBIO) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Macy's Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Macy's Inc trades at $24.57 (market cap $6.68B). The key difference: BridgeBio Pharma Inc is far larger — about 2.5× Macy's Inc's market cap, and Macy's Inc pays a 3.02% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | M | |
|---|---|---|
Market Cap | $16.61B | $6.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $26.21 |
52-Week Low | $47.29 | $12.11 |
Enterprise Value | $18.16B | $10.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Macy's (M) trades at $25.40, up 1.07% daily, with a bullish technical signal and positive earnings momentum after beating estimates in three consecutive quarters. The stock shows attractive valuation with a P/E of 10.5 and P/S of 0.31, while recent news highlights institutional buying and turnaround progress under the 'Bold New Chapter' strategy.
Outlook is cautiously optimistic with potential upside to the $30 analyst high target, supported by cost discipline and store revamps. Risks include competitive retail pressures and consumer spending volatility, but solid cash flow and low debt provide stability. The stock offers value with a 2.94% net margin and 14.36% ROE.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
